Last reviewed · How we verify
DMARDs
At a glance
| Generic name | DMARDs |
|---|---|
| Also known as | Disease-modifying antirheumatic drugs, Corticosteroid regimens that do not exceed 15 mg/day, NSAIDs, Methotrexate |
| Sponsor | Columbia University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis (PHASE2)
- The SetPoint System Safety & Performance Post-Approval Study
- IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD (PHASE1)
- Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis (PHASE3)
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines (PHASE3)
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
- Coronavirus Anxiety in Patients Using Biologic vs Conventional DMARDs
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |